Phase 4 Breast Cancer Trial, Not Yet Recruiting NCT05843292 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Breast Cancer
Back to Breast Cancer

Phase 4 Breast Cancer Trial, Not Yet Recruiting

NCT05843292
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women between 18 and 70 years of age.
  • People diagnosed with a single breast cancer (not both breasts) that has not spread to distant parts of the body, where the tumour measures at least 1 cm.
  • People whose breast cancer test results show: hormone receptors (ER and PR) are less than 10% positive, AND HER-2 results fall into one of the accepted low or negative categories on standard testing (confirm with trial site for exact test results).
  • People who have at least one tumour that can be measured using standard imaging guidelines.
  • People who have a recent tissue sample (core needle biopsy) from the main tumour available for testing.
  • People whose general health and ability to carry out daily activities has been rated as good (score of 0 or 1 on a standard scale) within 10 days before starting the study drug.
  • People who are not currently pregnant or breastfeeding, and who either are not able to become pregnant, OR who are able to become pregnant but agree to use strict contraception during treatment and for at least 6 months after the last dose.
  • People whose heart, liver, kidneys, and other organs are working well, as shown by recent blood tests and scans.
  • People who are willing and able to follow the study plan, understand the research process, and have signed a written consent form.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with cancer in both breasts, or breast cancer that has spread to other parts of the body (Stage IV).
  • People who have had a heart attack, a serious heart event, or certain heart procedures (such as stenting or bypass surgery) within the past 6 months, or who currently have or have previously had significant heart failure.
  • People whose immune system is weakened, or who have been taking steroid or immune-suppressing medicines within 7 days before starting the study drug.
  • People who have an autoimmune disease (where the immune system attacks the body) that has required ongoing treatment within the past 2 years.
  • People with a known history of active tuberculosis.
  • People who have had lung inflammation (pneumonitis) that required steroid treatment, or who currently have any type of active lung inflammation.
  • People with serious, active infections throughout the body, or other serious illnesses.
  • People who have been diagnosed with another cancer in the past 5 years, except for certain cured skin cancers or cervical carcinoma in situ.
  • People with a known HIV infection.
  • People with an active hepatitis B or hepatitis C infection.
  • People with a known allergy or intolerance to any of the medicines used in this trial or their ingredients.
  • People who have previously received chemotherapy, hormone therapy, biological therapy, or radiation therapy for any reason.
  • People who have previously been treated with certain immune checkpoint or T-cell targeting drugs (such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or similar medicines).
  • People who are currently in another clinical trial using an experimental medicine or device, if that treatment was given within the past 4 weeks (or within the past 12 months for experimental cancer or anti-growth treatments).
  • People who have received a live vaccine (such as measles, chickenpox, yellow fever, BCG, or nasal flu vaccine) within 30 days before starting the study drug.
  • People with a history of mental illness or substance abuse that may affect their ability to follow the trial requirements.
  • People who are pregnant or breastfeeding, or people who are able to become pregnant but are unwilling to use strict contraception.
  • People considered by the research team to be unsuitable for this study for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 0086-021-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 July 2023
Est. completion
31 December 2024

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Pathologic Complete Response (pCR) Rates

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov